GLPwatch
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus.
Diabetes Ther · 2020
Last updated 2026-08-28Semaglutide is a GLP-1 receptor agonist, a type of drug used to lower blood sugar in people with type 2 diabetes. In clinical trials, oral semaglutide was studied for its effectiveness, safety, and how well it was tolerated. The review focuses on results from the PIONEER program, which tested different doses and administration methods.
AI summary of the abstract below.
| Journal | Diabetes Ther, 2020 |
|---|---|
| Citations | 47 |
| Relative citation ratio | 2.53 |
| NIH percentile | 80 |
| Molecules | semaglutide |
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.
Verbatim abstract via PubMed 32725484 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.